• 

Remedy Negotiation With Competition Authorities

Remedy Negotiation with Competition Authorities  

When a competition authority (antitrust regulator) identifies potential anti-competitive conduct—such as mergers, cartels, abuse of dominance, or anti-competitive agreements—companies often engage in remedy negotiations to mitigate enforcement action or resolve competition concerns. Remedies can be structural (e.g., divestitures) or behavioral (e.g., commitments to change practices).

1. Types of Remedies in Competition Enforcement

Structural Remedies:

• Divestiture of business units or assets
• Licensing or transfer of intellectual property
• Spin-offs to reduce market concentration

Behavioral Remedies:

• Price or supply commitments
• Non-discrimination undertakings
• Compliance programs and reporting obligations

Key Risk: Remedies may be costly, operationally disruptive, or impact strategic plans.

Case References:

• United States v. Microsoft Corp., 2001 – Behavioral remedies included compliance monitoring and disclosure of APIs to competitors.
• European Commission v. GE/Honeywell, 2004 – Proposed remedies in a merger review were structural and behavioral, but ultimately the merger was blocked.

2. Negotiation Process with Competition Authorities

• Pre-filing consultation: Parties may engage informally to discuss potential remedies.
• Formal commitment submissions: Companies submit proposals addressing competitive concerns.
• Authority evaluation: Regulators assess sufficiency, effectiveness, and enforceability of proposed remedies.
• Negotiation and modification: Authorities may request adjustments, additional commitments, or more stringent measures.

Key Risk: Negotiations require early engagement and strategic concessions. Overly aggressive proposals may be rejected.

Case References:

• European Commission v. Intel, 2009 – Negotiated behavioral remedies to avoid formal fines, including non-exclusivity commitments.
• US v. AT&T/T-Mobile Merger, 2011 – Remedy negotiation involved divestiture proposals to maintain market competition.

3. Benefits of Engaging in Remedy Negotiation

• Reduces the risk of formal sanctions or litigation
• Demonstrates good faith compliance to authorities
• Can limit fines or penalties by showing proactive corrective action
• Preserves corporate reputation and shareholder confidence

Case References:

• Commission v. Telefónica, 2007 – Voluntary commitments led to the closure of the case without formal fines.
• US v. Oracle/PeopleSoft, 2005 – Negotiated remedies avoided prolonged litigation by divesting overlapping product lines.

4. Risks in Remedy Negotiation

1. Regulatory Risk: Remedies may not fully satisfy authorities, leading to fines or blocking.
2. Operational Risk: Structural remedies, such as divestitures, can disrupt business operations.
3. Strategic Risk: Behavioral remedies may constrain business flexibility.
4. Financial Risk: Cost of implementing remedies may be substantial.
5. Reputational Risk: Public disclosure of negotiations can affect market perception.

Case References:

• European Commission v. GE/Honeywell, 2004 – Merger blocked despite proposed remedies due to insufficient mitigation of competitive concerns.
• US v. Visa/Mastercard, 2003 – Behavioral remedies imposed but operational constraints and compliance costs were significant.

5. Legal Considerations in Remedy Negotiations

• Remedies must be clear, enforceable, and time-bound.
• Authorities often require monitoring and reporting obligations.
• Voluntary commitments can be binding under regulatory law (e.g., EU Article 9 commitments).
• Negotiations may involve confidentiality and privileged communications, but public disclosure may be required.

Case References:

• European Commission v. Intel, 2009 – Commitments were binding and monitored over several years.
• US v. American Airlines/DAL, 2010 – Divestiture and slot-swap remedies were legally binding and monitored.

6. Strategic Approach to Remedy Negotiation

• Early engagement: Initiate discussions before formal enforcement.
• Benchmarking: Compare proposed remedies with prior cases to demonstrate feasibility.
• Robust compliance plan: Include internal controls to support behavioral commitments.
• Negotiation leverage: Use evidence of limited anti-competitive effects or market benefits.
• Documentation: Maintain detailed records to demonstrate good faith and compliance.

7. Summary Table of Key Cases

Conclusion

Remedy negotiation with competition authorities is a strategic tool to manage regulatory risk, mitigate enforcement action, and preserve operational continuity. Companies must balance:

• Compliance and legal obligations
• Operational and financial feasibility of remedies
• Stakeholder interests and reputational impact

Best practices: early engagement, evidence-based proposals, robust compliance programs, and clear documentation.

RELATED Blog

Corporate Law at Afghanistan

Corporate Law at Albania

Corporate Law at Algeria

Corporate Law at American Samoa (US)

Corporate Law at Bangladesh

Corporate Law at Andorra

Corporate Law at Angola

Corporate Law at Antigua and Barbuda

Corporate Law at Anguilla (BOT)

Corporate Law at Argentina